Given its close association with tumour immune regulation, CD70‐targeted therapies not only enable direct elimination of CD70‐positive tumour cells but also hold potential to activate effector immune responses and remodel the immunosuppressive microenvironment. The gene discussed is CD70; the disease is neoplasm.